Trial Profile
A Retrospective Study of Vedolizumab in Patients with Primary Sclerosis Cholangitis (PSC) and Inflammatory Bowel Disease (IBD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2018
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Primary sclerosing cholangitis; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018.
- 17 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018